OpenURL Connection Search

Select item for more details and to access through your institution.

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.
Published in:
Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-40966-8
By:
- Coffey, David G.;
- Maura, Francesco;
- Gonzalez-Kozlova, Edgar;
- Diaz-Mejia, J. Javier;
- Luo, Ping;
- Zhang, Yong;
- Xu, Yuexin;
- Warren, Edus H.;
- Dawson, Travis;
- Lee, Brian;
- Xie, Hui;
- Smith, Eric;
- Ciardiello, Amanda;
- Cho, Hearn J.;
- Rahman, Adeeb;
- Kim-Schulze, Seunghee;
- Diamond, Benjamin;
- Lesokhin, Alexander;
- Kazandjian, Dickran;
- Pugh, Trevor J.
Publication type:
Article
Antigen–immunostimulatory oligonucleotide conjugates: mechanisms and applications.
Published in:
Immunological Reviews, 2004, v. 199, n. 1, p. 217, doi. 10.1111/j.0105-2896.2004.00149.x
By:
- Datta, Sandip K.;
- Cho, Hearn J.;
- Takabayashi, Kenji;
- Horner, Anthony A.;
- Raz, Eyal
Publication type:
Article
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.
Published in:
Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1085893
By:
- Wong, Sandy;
- Hamidi, Habib;
- Costa, Luciano J.;
- Bekri, Selma;
- Neparidze, Natalia;
- Vij, Ravi;
- Nielsen, Tina G.;
- Raval, Aparna;
- Sareen, Rajan;
- Wassner-Fritsch, Elisabeth;
- Cho, Hearn J.
Publication type:
Article
Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding.
Published in:
PLoS ONE, 2016, v. 11, n. 2, p. 1, doi. 10.1371/journal.pone.0148762
By:
- Newman, Joseph A.;
- Cooper, Christopher D. O.;
- Roos, Anette K.;
- Aitkenhead, Hazel;
- Oppermann, Udo C. T.;
- Cho, Hearn J.;
- Osman, Roman;
- Gileadi, Opher
Publication type:
Article
Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>.
Published in:
American Journal of Hematology, 2020, v. 95, n. 2, p. E51, doi. 10.1002/ajh.25695
By:
- Barley, Kevin;
- Sanchez, Larysa;
- Cho, Hearn J.;
- Parekh, Samir;
- Madduri, Deepu;
- Richter, Joshua;
- Isola, Luis;
- Goldstein, Talia;
- Dhadwal, Amishi;
- Zarychta, Katarzyna;
- Sanchez, Gillian Morgan;
- Catamero, Donna;
- Verina, Daniel;
- Florendo, Erika;
- Yum, Moon‐hee;
- La, Lisa;
- Gullie, Jude;
- Chan, Elaine;
- Jagannath, Sundar;
- Chari, Ajai
Publication type:
Article
Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Published in:
2021
By:
- Martin, Thomas G.;
- Shah, Nina;
- Richter, Joshua;
- Vesole, David H.;
- Wong, Sandy W.;
- Huang, Chiung‐Yu;
- Madduri, Deepu;
- Jagannath, Sundar;
- Siegel, David S.;
- Biran, Noa;
- Wolf, Jeffrey L.;
- Parekh, Samir;
- Cho, Hearn J.;
- Munster, Pamela;
- Richard, Shambavi;
- Ziti‐Ljajic, Samira;
- Chari, Ajai;
- Huang, Chiung-Yu;
- Ziti-Ljajic, Samira
Publication type:
journal article

Found: 6

Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma.

Antigen–immunostimulatory oligonucleotide conjugates: mechanisms and applications.

Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM.

Structures of Two Melanoma-Associated Antigens Suggest Allosteric Regulation of Effector Binding.

Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>.

Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.